Alcohol Research Consortium in HIV: Biostatistics and Method Core
HIV 酒精研究联盟:生物统计学和方法核心
基本信息
- 批准号:10304373
- 负责人:
- 金额:$ 22.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-10 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AbstinenceAccountingAddressAffectAgeAlcohol consumptionAlcoholsAreaBiological MarkersBiometryBiostatistical MethodsCardiovascular DiseasesCaringClinicalCognitionCollaborationsCommunitiesContinuity of Patient CareDataData SourcesDevelopmentDisease remissionEffectivenessElectronic Health RecordEnsureEpidemicEpidemiologic MethodsEpidemiologyEventFibrinogenGoalsGrantHIVHIV InfectionsHeterogeneityIndividualInterventionLeadershipLearningLiver diseasesMachine LearningMalignant NeoplasmsMeasurementMeasuresMedical RecordsMethodologyMethodsNeighborhoodsOutcomePatient Outcomes AssessmentsPatient Self-ReportPersonsPopulationProcessPropertyPublicationsRecording of previous eventsRecoveryRelapseResearchResearch DesignResearch PersonnelResearch Project GrantsResearch SupportResourcesRiskScienceSiteSourceStatistical MethodsTreatment outcomealcohol abuse therapyalcohol interventionalcohol measurementalcohol relapsealcohol researchalcohol riskalcohol use disorderbarrier to carebasecohortcomorbiditycomparison groupcontextual factorsdata managementdesignevidence basefrailtyimplementation scienceimprovedinnovationinsightnovelpredictive modelingsocial determinantssocial health determinantssuccesssupervised learningtreatment as preventionunsupervised learninguptake
项目摘要
HIV Treatment as Prevention (TASP) is critical to Ending the HIV Epidemic (EHE). At-risk alcohol use and alcohol
used disorder (AUD) are barriers to TASP through direct impacts on the HIV Care Continuum (HIV-CC). The
impact of alcohol use on other comorbidities among persons with HIV (PWH) including liver disease,
cardiovascular disease (CVD), malignancy, cognition, and frailty is increasingly relevant as persons age with
HIV. The goals of ARCH are to implement evidence based alcohol interventions across the alcohol use spectrum
(from no use, low risk, at-risk, AUD, recovery (low risk use or no use) or remission (no use) and relapse); to
understand the contextual factors (i.e., social determinants of health [SDH] from the individual to community
level) impact on alcohol use spectrum, the alcohol care continuum (Alc-CC), HIV –CC, and comorbidities; and
to determine the optimal alcohol targets (abstinence, reduction in WHO risk score) and use different sources of
alcohol measures to maximize information for determining alcohol status. The goal of the ARCH Biostatistics
and Methods Core (ARCH-BMC) is to ensure that high quality contemporary research is carried out in terms of
formulating research questions, study design, and analyses of the projects included within this P01. The ARCH-
BMC will provide expertise and leadership in epidemiology and biostatistics in the quantitative support of the
consortium. As has been done in prior years of ARCH, our group we will increase the depth to which research
questions are pursued, resulting in increased quantity, quality, and effectiveness of the consortium research
objectives, including the overall goals of the P01 (implementation science of alcohol interventions, impact of
social determinants of health, and measures of alcohol). To accomplish this goal, we propose activities for both
project support and methodological development. The specific aims of ARCH BMC are: 1) To provide wide-
ranging, high-quality epidemiological and statistical support to ARCH, 2) To provide leadership in developing
new statistical and epidemiological methods that address deficiencies in causal methods relevant to the novel
research aims of the consortium, and 3) To integrate supplemental data sources and assessment of novel
methodologies across the alcohol care continuum. ARCH-BMC adds value by contributing quantitative and
epidemiological perspectives to the ARCH P01 scientific agenda and simultaneously operationalizing the science
with appropriate study designs, data management, and analytical methodology. Successful research is
accomplished by creating comprehensive partnerships that provide expertise throughout the entire research
process, from the beginning with the conceptualization of the research question through all steps to publication.
Innovation and improved research insights are obtained when collaborations integrate novel and improved
methodology, uncovering further methodological challenges and motivating new areas for research. By
supporting the research projects and working collaboratively with the transdisciplinary ARCH team, ARCH-BMC
will increase the likelihood of success of ARCH in achieving its overall project goals.
HIV 治疗作为预防 (TASP) 对于结束 HIV 流行 (EHE) 至关重要。
使用障碍 (AUD) 通过对 HIV 护理连续体 (HIV-CC) 的直接影响而成为 TASP 的障碍。
饮酒对艾滋病毒感染者(PWH)其他合并症的影响,包括肝病、
随着人们年龄的增长,心血管疾病(CVD)、恶性肿瘤、认知和虚弱变得越来越重要
ARCH 的目标是在整个饮酒范围内实施基于证据的酒精干预措施。
(从不使用、低风险、有风险、AUD、恢复(低风险使用或不使用)或缓解(不使用)和复发);
了解背景因素(即从个人到社区的健康社会决定因素 [SDH]
水平)对酒精使用谱、酒精护理连续体(Alc-CC)、HIV –CC 和合并症的影响;
确定酒精最佳目标(戒酒、降低世界卫生组织风险评分)并使用不同来源的酒精
ARCH 生物统计学的目标是最大限度地利用酒精测量信息来确定酒精状况。
和方法核心(ARCH-BMC)是为了确保在以下方面进行高质量的当代研究:
制定本 P01 中包含的研究问题、研究设计和项目分析。
BMC 将提供流行病学和生物统计学方面的专业知识和领导力,为
正如 ARCH 前几年所做的那样,我们小组将增加研究的深度。
提出问题,从而提高联盟研究的数量、质量和有效性
目标,包括 P01 的总体目标(酒精干预措施的实施科学、
健康的社会决定因素和酒精测量)为了实现这一目标,我们建议针对这两个目标开展活动。
ARCH BMC 的具体目标是: 1) 提供广泛的支持和方法开发。
为 ARCH 提供范围广泛、高质量的流行病学和统计支持,2) 领导制定
新的统计和流行病学方法,解决与小说相关的因果方法的缺陷
该联盟的研究目标,以及3)整合补充数据源和新颖的评估
ARCH-BMC 的方法论通过定量和贡献来增加价值。
ARCH P01 科学议程的流行病学视角并同时实施科学
适当的研究设计、数据管理和分析方法是成功的研究。
通过建立全面的合作伙伴关系来实现,在整个研究过程中提供专业知识
过程,从研究问题的概念化开始到发表的所有步骤。
当合作整合新颖和改进的内容时,就会获得创新和改进的研究见解
方法论,揭示进一步的方法论挑战并激发新的研究领域。
支持研究项目并与跨学科 ARCH 团队 ARCH-BMC 合作
将增加 ARCH 成功实现其总体项目目标的可能性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bryan Lau其他文献
Bryan Lau的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bryan Lau', 18)}}的其他基金
Lung and HIV Analytical Data Coordinating Center (LHAD-CC)
肺和 HIV 分析数据协调中心 (LHAD-CC)
- 批准号:
8638405 - 财政年份:2013
- 资助金额:
$ 22.69万 - 项目类别:
Lung and HIV Analytical Data Coordinating Center (LHAD-CC)
肺和 HIV 分析数据协调中心 (LHAD-CC)
- 批准号:
9320887 - 财政年份:2013
- 资助金额:
$ 22.69万 - 项目类别:
Lung and HIV Analytical Data Coordinating Center (LHAD-CC)
肺和 HIV 分析数据协调中心 (LHAD-CC)
- 批准号:
8743255 - 财政年份:2013
- 资助金额:
$ 22.69万 - 项目类别:
Global Immunological Response to Effective Antiretroviral Therapy (GiREAT:CD4)
对有效抗逆转录病毒治疗的整体免疫反应 (GiREAT:CD4)
- 批准号:
8693046 - 财政年份:2013
- 资助金额:
$ 22.69万 - 项目类别:
Biostatistics and Epidemiology Methodology Core
生物统计学和流行病学方法学核心
- 批准号:
10153643 - 财政年份:2012
- 资助金额:
$ 22.69万 - 项目类别:
Biomarkers, Therapy, and Mortality in the Evolving HIV Epidemic
不断演变的艾滋病毒流行病中的生物标志物、治疗和死亡率
- 批准号:
7229276 - 财政年份:2007
- 资助金额:
$ 22.69万 - 项目类别:
Biomarkers, Therapy, and Mortality in the Evolving HIV Epidemic
不断演变的艾滋病毒流行病中的生物标志物、治疗和死亡率
- 批准号:
7804576 - 财政年份:2007
- 资助金额:
$ 22.69万 - 项目类别:
Biomarkers, Therapy, and Mortality in the Evolving HIV Epidemic
不断演变的艾滋病毒流行病中的生物标志物、治疗和死亡率
- 批准号:
8061594 - 财政年份:2007
- 资助金额:
$ 22.69万 - 项目类别:
相似国自然基金
上市公司所得税会计信息公开披露的经济后果研究——基于“会计利润与所得税费用调整过程”披露的检验
- 批准号:72372025
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
兔死狐悲——会计师事务所同侪CPA死亡的审计经济后果研究
- 批准号:72302197
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境治理目标下的公司财务、会计和审计行为研究
- 批准号:72332003
- 批准年份:2023
- 资助金额:166 万元
- 项目类别:重点项目
签字注册会计师动态配置问题研究:基于临阵换师视角
- 批准号:72362023
- 批准年份:2023
- 资助金额:28 万元
- 项目类别:地区科学基金项目
异常获利、捐赠与会计信息操纵:基于新冠疫情的准自然实验研究
- 批准号:72372061
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
相似海外基金
Providing Tobacco Treatment to Patients Undergoing Lung Cancer Screening at MedStar Health: A Randomized Trial
为 MedStar Health 接受肺癌筛查的患者提供烟草治疗:一项随机试验
- 批准号:
10654115 - 财政年份:2023
- 资助金额:
$ 22.69万 - 项目类别:
Antibody-based therapy for fentanyl-related opioid use disorder
基于抗体的芬太尼相关阿片类药物使用障碍治疗
- 批准号:
10831206 - 财政年份:2023
- 资助金额:
$ 22.69万 - 项目类别:
Comparative Risk of Oral Complications Associated with Medications for Opioid Use Disorder: A Mixed-Methods Approach
与阿片类药物使用障碍药物相关的口腔并发症的风险比较:混合方法
- 批准号:
10765049 - 财政年份:2023
- 资助金额:
$ 22.69万 - 项目类别:
Determining the Influence of Clinicodemographic, Biologic and SDOH Factors in Racial and Ethnic Disparities in the Prognosis of Alcohol-Associated Liver Disease
确定临床人口统计学、生物和 SDOH 因素对酒精相关性肝病预后中种族和民族差异的影响
- 批准号:
10785492 - 财政年份:2023
- 资助金额:
$ 22.69万 - 项目类别:
Improving outcomes for substance-affected families in the child welfare system
改善儿童福利系统中受药物影响的家庭的成果
- 批准号:
10734742 - 财政年份:2023
- 资助金额:
$ 22.69万 - 项目类别: